International Journal of Antimicrobial Agents
Volume 36, Issue 1 , Pages 69-72 , July 2010

In vitro activity of oritavancin against community-associated meticillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA)

Received 9 November 2009 ,Accepted 26 February 2010.

References 

  1. Poulakou G, Giamarellou H. Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens. Expert Opin Investig Drugs. 2008;17:225–243
  2. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant Staphylococcus aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666–674
  3. Said-Salim B, Mathema B, Kreiswirth BN. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging pathogen. Infect Control Hosp Epidemiol. 2003;24:451–455
  4. McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK, Tenover FC. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol. 2003;41:5113–5120
  5. Zhang K, McClure JA, Elsayed S, Louie T, Conly JM. Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2005;43:5026–5033
  6. Lina G, Piémont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, et al. Involvement of Panton–Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis. 1999;29:1128–1132
  7. Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, Davidson MG, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant Staphylococcus aureus. Lancet. 2006;367:731–739
  8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Eighteenth informational supplement. Document M100-S18. Wayne, PA: CLSI; 2008.
  9. Clinical and Laboratory Standards Institute. Methods for determining bactericidal activity of antimicrobial agents; approved guidelines. Document M26-A. Wayne, PA: CLSI; 1999.
  10. Johnson LB, Jose J, Yousif F, Pawlak J, Saravolatz L. Prevalence of colonization with community-associated methicillin-resistant Staphylococcus aureus among end-stage renal disease patients and healthcare workers. Infect Control Hosp Epidemiol. 2009;30:4–8
  11. Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653–665
  12. Biavasco F, Vignaroli C, Lupidi R, Manso E, Facinelli B, Varaldo PE. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob Agents Chemother. 1997;41:2165–2172
  13. Zeckel ML, Preston DA, Allen BS. In vitro activities of LY333328 and comparative agents against nosocomial Gram-positive pathogens collected in a 1997 global surveillance study. Antimicrob Agents Chemother. 2000;44:1370–1374
  14. Wasilewski M, Disch D, McGill J, Harris H, O’Riordan W, Zeckel ML. Equivalence of shorter course therapy with oritavancin compared to vancomycin/cephalexin in complicated skin/skin structure infections. In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 16–19 December 2001, Chicago, IL. ASM Press: Washington, DC; 2001;Poster UL-18
  15. Giamarellou H, O’Riordan W, Harris H, Porter S, Loutit J. Phase III trial comparing 3–7 days of oritavancin versus 10–14 days of vancomycin/cephalexin in the treatment of patients with complicated skin/skin structure infections (CSSI). In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 14–17 September 2003, Chicago, IL. Washington, DC: ASM Press; 2003;Poster L-739

PII: S0924-8579(10)00116-0

doi: 10.1016/j.ijantimicag.2010.02.023

International Journal of Antimicrobial Agents
Volume 36, Issue 1 , Pages 69-72 , July 2010

Article Tools